TWM
CADL icon

Tanager Wealth Management’s Candel Therapeutics CADL Stock Holding History

Tanager Wealth Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.04M Hold
198,175
– – 0.18% 44
2026
Q1 		$971K Hold
198,175
– – 0.09% 55
2025
Q4 		$1.12M Hold
198,175
– – 0.11% 51
2025
Q3 		$1.01M Buy
198,175
+1,544
+0.8% +$8.92K 0.11% 55
2025
Q2 		$995K Buy
+196,631
New +$1.01M 0.12% 52

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Tanager Wealth Management's CADL Position: Q2 2026 in Review

Tanager Wealth Management held its Candel Therapeutics (CADL) position steady in Q2 2026 at 198,175 shares worth $2.04M. The position accounts for 0.18% of the portfolio, ranked #44.

Tanager Wealth Management first reported a position in CADL in Q2 2025 and has held it in 5 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Tanager Wealth Management held 198,175 shares of Candel Therapeutics worth $2.04M as of Q2 2026.
  • Tanager Wealth Management left its Candel Therapeutics share count unchanged in Q2 2026.
  • Candel Therapeutics made up 0.18% of Tanager Wealth Management's portfolio in Q2 2026, its #44 holding.
  • Tanager Wealth Management first reported a position in Candel Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Tanager Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.